CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug

10-01-2008

Leuchemix Corporation announced that permission to undertake clinical safety trials of its drug LC-1, for leukemia, has been granted and that the sponsored trial will begin shortly

Leuchemix Corporation announced that permission to undertake clinical safety trials of its drug LC-1, for leukemia, has been granted and that the sponsored trial will begin shortly. CombiMatrix Corporation (Nasdaq:CBMX) owns one third of Leuchemix.

ABOUT COMBIMATRIX CORPORATION

CombiMatrix Corporation is a diversified biotechnology business, through the development of proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security markets, as well as other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce customizable, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. CombiMatrix Molecular Diagnostics, Inc. ("CMDX"), a wholly owned subsidiary of the Company located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis.

Additional information about CombiMatrix Corporation is available at www.combimatrix.com or call toll free: 1-800-710-0624.